Market closedNon-fractional
Syndax Pharmaceuticals/SNDX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Ticker
SNDX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
184
Website
www.syndax.com
SNDX Metrics
BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$3.24
EPS
1.01
Beta
-
Dividend rate
Price and volume
Market cap
$1.8B
Beta
1.01
Financial strength
Current ratio
8.934
Quick ratio
8.872
Long term debt to equity
0.068
Total debt to equity
0.282
Interest coverage (TTM)
-1,181.40%
Management effectiveness
Return on assets (TTM)
-32.84%
Return on equity (TTM)
-51.89%
Valuation
Price to book
3.57
Price to tangible book (TTM)
3.57
Price to free cash flow (TTM)
-7.49
Growth
Earnings per share change (TTM)
33.94%
3-year earnings per share growth
19.88%
What the Analysts think about SNDX
Analyst Ratings
Majority rating from 13 analysts.
SNDX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$72M
-0.00%
Profit margin
0.00%
NaN%
SNDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.64
-$0.73
-$1.00
-$0.85
-
Expected
-$0.73
-$0.80
-$0.99
-$0.98
-$0.92
Surprise
-12.59%
-8.23%
0.58%
-13.14%
-
SNDX News
AllArticlesVideos
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
PRNewsWire·3 weeks ago
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
PRNewsWire·4 weeks ago
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
PRNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Syndax Pharmaceuticals stock?
Syndax Pharmaceuticals (SNDX) has a market cap of $1.8B as of July 05, 2024.
What is the P/E ratio for Syndax Pharmaceuticals stock?
The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of July 05, 2024.
Does Syndax Pharmaceuticals stock pay dividends?
No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Syndax Pharmaceuticals dividend payment date?
Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Syndax Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.